According to Citi analysts, Amgen’s acquisition of Dark Blue could further drive the strength of Amgen’s early oncology ...

SEATTLE, WA / ACCESS Newswire / March 20, 2025 / Aptevo Therapeutics (APVO), a clinical-stage biotechnology company developing novel bispecific immuno-oncology therapeutics based on its proprietary ...

Company to host analyst call at 5:00pm ET today to discuss progress to date and expansion of clinical trial SOUTH SAN ...

In a groundbreaking development, First Ascent Biomedical unveils a compelling narrative of resilience and innovation through ...

Patients with acute myeloid leukemia (AML) in remission for 3 years have survival rates similar to the general population, but long-term needs remain poorly understood. A retrospective analysis showed ...

Amgen is committed to reducing drug costs, expanding its AmgenNow program, and investing in US manufacturing to gain tariff ...

90% of frontline AML patients achieved remission with mipletamig plus ven/aza, surpassing the 66% rate seen with ven/aza alone. No cytokine release syndrome (CRS) has been reported in the RAINIER ...

The study covered in this summary was published on ssrn.com as a preprint and has not yet been peer reviewed. Cytarabine plus an anthracycline has been the standard AML induction regimen for decades, ...

SELLAS Life Sciences Virtual R&D Day -- October 29, 2025: Advancing Novel Therapies in Acute Myeloid Leukemia (AML): An Overview of the Ongoing Phase 3 REGAL Trial of Galinpepimut-S (GPS) and SLS009 ...

Tatiana Schlossberg, President John F. Kennedy's granddaughter, has died. Here's what to know about acute myeloid leukemia ...